March 2010

March 23, 2010
0 Comments

Another Stem Cell Trial To Begin

This is awesome news! In the first federal-government-approved clinical trial of its kind in the U.S., patients with amyotrophic lateral sclerosis (ALS) will be treated with their own stem cells. The aim is to hopefully slow the progress of the fatal, neurodegenerative disease. TCA Cellular Therapy of Covington, a privately held stem-cell research and development [...]

Read the full article →
March 10, 2010
1 Comment

Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis

A new potential treatment on the horizon. I’m so excited! Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that its fast skeletal muscle troponin activator, CK-2017357, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig’s Disease. CK-2017357 is [...]

Read the full article →
March 8, 2010
0 Comments

ALS SOD1 Trial: A ‘Watershed Moment’ | Quest Magazine Online

  Isis Pharmaceuticals of Carlsbad, Calif., has begun a phase 1 clinical trial of its experimental compound ISIS-SOD1-Rx in people with familial (inherited) ALS caused by toxic SOD1 protein molecules. “This is a watershed moment,” said R. Rodney Howell, a metabolic disease specialist and chairman of the MDA Board of Directors. “More than 30 people [...]

Read the full article →